Timothy A Shepherd

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Design and synthesis of a novel series of 1,2-disubstituted cyclopentanes as small, potent potentiators of 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid (AMPA) receptors
    Timothy A Shepherd
    NPS Allelix Corporation, 6850 Goreway Drive, Mississaugua, Ontario L4V 1V7, Canada
    J Med Chem 45:2101-11. 2002
  2. ncbi A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation
    Andrew G Geiser
    Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Endocrinology 146:4524-35. 2005
  3. ncbi Progress toward the discovery and development of efficacious BACE inhibitors
    Timothy B Durham
    Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Opin Drug Discov Devel 9:776-91. 2006
  4. ncbi Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety
    Timothy I Richardson
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Bioorg Med Chem Lett 17:3544-9. 2007
  5. ncbi A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats
    Conrad W Hummel
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Med Chem 48:6772-5. 2005

Collaborators

Detail Information

Publications5

  1. ncbi Design and synthesis of a novel series of 1,2-disubstituted cyclopentanes as small, potent potentiators of 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid (AMPA) receptors
    Timothy A Shepherd
    NPS Allelix Corporation, 6850 Goreway Drive, Mississaugua, Ontario L4V 1V7, Canada
    J Med Chem 45:2101-11. 2002
    ..Compound (R,R)-10 represents a potent, novel potentiator of iGluR4 flip receptors (EC(50) = 22.6 nM)...
  2. ncbi A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation
    Andrew G Geiser
    Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Endocrinology 146:4524-35. 2005
    ..Collectively, these data show that LY2066948 exhibits a tissue-specific profile consistent with strong antagonist activity in the uterus, agonist activity in bone, and minimal effects in the ovaries...
  3. ncbi Progress toward the discovery and development of efficacious BACE inhibitors
    Timothy B Durham
    Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Opin Drug Discov Devel 9:776-91. 2006
    ..The recent literature relating to the discovery and development of efficacious BACE inhibitors is reviewed with particular emphasis on the patent literature...
  4. ncbi Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety
    Timothy I Richardson
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Bioorg Med Chem Lett 17:3544-9. 2007
    ..The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation...
  5. ncbi A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats
    Conrad W Hummel
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Med Chem 48:6772-5. 2005
    ....